Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COL-Micro-HF: Colchicine in Heart Failure with EF > 40%
NCT06217120Phase 3Not yet recruiting
- Sponsor
- Montréal Heart Institute
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine in heart failure with preserved ejection fraction (HFpEF), coronary microvascular disease (CMD), sponsored by Montréal Heart Institute. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)coronary microvascular disease (CMD)
Beyond the preview
Go deeper on NCT06217120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217120.